Cargando…
Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation
Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiolo...
Autores principales: | Abuazzam, Farah, Dubrawka, Casey, Abdulhadi, Tarek, Amurao, Gwendolyn, Alrata, Louai, Yaseen Alsabbagh, Dema, Alomar, Omar, Alhamad, Tarek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419906/ https://www.ncbi.nlm.nih.gov/pubmed/37568318 http://dx.doi.org/10.3390/jcm12154916 |
Ejemplares similares
-
Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
por: Pottebaum, April A., et al.
Publicado: (2020) -
Patterns in Use and Transplant Outcomes Among Adult Recipients of Kidneys From Deceased Donors With COVID-19
por: Ji, Mengmeng, et al.
Publicado: (2023) -
Gross hematuria after kidney transplantation
por: Alhamad, Tarek, et al.
Publicado: (2013) -
Repeat kidney transplant recipients with active rejection have elevated donor‐derived cell‐free DNA
por: Mehta, Shikha G., et al.
Publicado: (2018) -
The association of center volume with transplant outcomes in selected high-risk groups in kidney transplantation
por: Merzkani, Massini, et al.
Publicado: (2023)